TY  - JOUR
AU  - Adžić, Miroslav
AU  - Brkić, Željka
AU  - Mitić, Miloš
AU  - Francija, Ester
AU  - Jovičić, Milica J.
AU  - Radulović, Jelena
AU  - Marić, Nađa P.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1939
AB  - Background: Mounting evidence demonstrates enhanced systemic levels of inflammatory mediators in depression, indicating that inflammation may play a role in the etiology and course of mood disorders. Indeed, proinflammatory cytokines induce a behavioral state of conservation- withdrawal resembling human depression, characterized by negative mood, fatigue, anhedonia, psychomotor retardation, loss of appetite, and cognitive deficits. Neuroinflammation also contributes to non-responsiveness to current antidepressant (AD) therapies. Namely, response to conventional AD medications is associated with a decrease in inflammatory biomarkers, whereas resistance to treatment is accompanied by increased inflammation. Methods: In this review, we will discuss the utility and shortcomings of pharmacologic AD treatment strategies focused on inflammatory pathways, applied alone or as an adjuvant component to current AD therapies. Results: Mechanisms of cytokine actions on behavior involve activation of inflammatory pathways in the brain, resulting in changes of neurotransmitter metabolism, neuroendocrine function, and neuronal plasticity. Selective serotonin reuptake inhibitors exhibit the most beneficial effects in restraining the inflammation markers in depression. Different anti-inflammatory agents exhibit AD effects via modulating neurotransmitter systems, neuroplasticity markers and glucocorticoid receptor signaling. Anti-inflammatory add-on therapy in depression highlights such treatment as a candidate for enhancement strategy in patients with moderate-to-severe depression. Conclusion: The interactions between the immune system and CNS are not only involved in shaping behavior, but also in responding to therapeutics. Even though, substantial evidence from animal and human research support a beneficial effect of anti-inflammatory add-on therapy in depression, further research with special attention on safety, particularly during prolonged periods of antiinflammatory co-treatments, is required.
T2  - Current Neuropharmacology
T1  - Therapeutic Strategies for Treatment of Inflammation-related Depression
VL  - 16
IS  - 2
SP  - 176
EP  - 209
DO  - 10.2174/1570159X15666170828163048
ER  - 

@article{
author = "Adžić, Miroslav and Brkić, Željka and Mitić, Miloš and Francija, Ester and Jovičić, Milica J. and Radulović, Jelena and Marić, Nađa P.",
year = "2018",
abstract = "Background: Mounting evidence demonstrates enhanced systemic levels of inflammatory mediators in depression, indicating that inflammation may play a role in the etiology and course of mood disorders. Indeed, proinflammatory cytokines induce a behavioral state of conservation- withdrawal resembling human depression, characterized by negative mood, fatigue, anhedonia, psychomotor retardation, loss of appetite, and cognitive deficits. Neuroinflammation also contributes to non-responsiveness to current antidepressant (AD) therapies. Namely, response to conventional AD medications is associated with a decrease in inflammatory biomarkers, whereas resistance to treatment is accompanied by increased inflammation. Methods: In this review, we will discuss the utility and shortcomings of pharmacologic AD treatment strategies focused on inflammatory pathways, applied alone or as an adjuvant component to current AD therapies. Results: Mechanisms of cytokine actions on behavior involve activation of inflammatory pathways in the brain, resulting in changes of neurotransmitter metabolism, neuroendocrine function, and neuronal plasticity. Selective serotonin reuptake inhibitors exhibit the most beneficial effects in restraining the inflammation markers in depression. Different anti-inflammatory agents exhibit AD effects via modulating neurotransmitter systems, neuroplasticity markers and glucocorticoid receptor signaling. Anti-inflammatory add-on therapy in depression highlights such treatment as a candidate for enhancement strategy in patients with moderate-to-severe depression. Conclusion: The interactions between the immune system and CNS are not only involved in shaping behavior, but also in responding to therapeutics. Even though, substantial evidence from animal and human research support a beneficial effect of anti-inflammatory add-on therapy in depression, further research with special attention on safety, particularly during prolonged periods of antiinflammatory co-treatments, is required.",
journal = "Current Neuropharmacology",
title = "Therapeutic Strategies for Treatment of Inflammation-related Depression",
volume = "16",
number = "2",
pages = "176-209",
doi = "10.2174/1570159X15666170828163048"
}

Adžić, M., Brkić, Ž., Mitić, M., Francija, E., Jovičić, M. J., Radulović, J.,& Marić, N. P.. (2018). Therapeutic Strategies for Treatment of Inflammation-related Depression. in Current Neuropharmacology, 16(2), 176-209.
https://doi.org/10.2174/1570159X15666170828163048

Adžić M, Brkić Ž, Mitić M, Francija E, Jovičić MJ, Radulović J, Marić NP. Therapeutic Strategies for Treatment of Inflammation-related Depression. in Current Neuropharmacology. 2018;16(2):176-209.
doi:10.2174/1570159X15666170828163048 .

Adžić, Miroslav, Brkić, Željka, Mitić, Miloš, Francija, Ester, Jovičić, Milica J., Radulović, Jelena, Marić, Nađa P., "Therapeutic Strategies for Treatment of Inflammation-related Depression" in Current Neuropharmacology, 16, no. 2 (2018):176-209,
https://doi.org/10.2174/1570159X15666170828163048 . .

TY  - JOUR
AU  - Jovičić, Milica J.
AU  - Lukić, Iva
AU  - Radojčić, Marija
AU  - Adžić, Miroslav
AU  - Marić, Nađa P.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/723
AB  - Glucocorticoid resistance is a common finding in major depressive disorder. Increased glucocorticoid receptor (GR) phosphorylation at serine 226 is associated with increased glucocorticoid resistance. Previously we have demonstrated that depressed patients exhibit higher levels of GR phosphorylated at serine 226 compared to healthy controls. The enzyme that is involved in this specific GR phosphorylation is c-Jun N-terminal kinase (JNK). We propose that modulation of glucocorticoid phosphorylation at serine 226, by targeting JNK signaling pathway, could be a potential strategy for antidepressant treatment. We base this assumption on the results of previous research that examined GR phosphorylation and JNK signaling in animal models and human studies. We also discuss the potential challenges in targeting JNK signaling pathway in depression. (C) 2015 Elsevier Ltd. All rights reserved.
T2  - Medical Hypotheses
T1  - Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression
VL  - 85
IS  - 3
SP  - 291
EP  - 294
DO  - 10.1016/j.mehy.2015.05.015
ER  - 

@article{
author = "Jovičić, Milica J. and Lukić, Iva and Radojčić, Marija and Adžić, Miroslav and Marić, Nađa P.",
year = "2015",
abstract = "Glucocorticoid resistance is a common finding in major depressive disorder. Increased glucocorticoid receptor (GR) phosphorylation at serine 226 is associated with increased glucocorticoid resistance. Previously we have demonstrated that depressed patients exhibit higher levels of GR phosphorylated at serine 226 compared to healthy controls. The enzyme that is involved in this specific GR phosphorylation is c-Jun N-terminal kinase (JNK). We propose that modulation of glucocorticoid phosphorylation at serine 226, by targeting JNK signaling pathway, could be a potential strategy for antidepressant treatment. We base this assumption on the results of previous research that examined GR phosphorylation and JNK signaling in animal models and human studies. We also discuss the potential challenges in targeting JNK signaling pathway in depression. (C) 2015 Elsevier Ltd. All rights reserved.",
journal = "Medical Hypotheses",
title = "Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression",
volume = "85",
number = "3",
pages = "291-294",
doi = "10.1016/j.mehy.2015.05.015"
}

Jovičić, M. J., Lukić, I., Radojčić, M., Adžić, M.,& Marić, N. P.. (2015). Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression. in Medical Hypotheses, 85(3), 291-294.
https://doi.org/10.1016/j.mehy.2015.05.015

Jovičić MJ, Lukić I, Radojčić M, Adžić M, Marić NP. Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression. in Medical Hypotheses. 2015;85(3):291-294.
doi:10.1016/j.mehy.2015.05.015 .

Jovičić, Milica J., Lukić, Iva, Radojčić, Marija, Adžić, Miroslav, Marić, Nađa P., "Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression" in Medical Hypotheses, 85, no. 3 (2015):291-294,
https://doi.org/10.1016/j.mehy.2015.05.015 . .

TY  - JOUR
AU  - Jovičić, Milica
AU  - Marić, Nađa P.
AU  - Soldatovic, Ivan
AU  - Lukić, Iva
AU  - Andrić, Sanja
AU  - Mihaljević, Marina
AU  - Pavlović, Zorana
AU  - Mitić, Miloš
AU  - Adžić, Miroslav
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/707
AB  - Objectives. To develop a structural equation model of negative affectivity (NA) that involves interaction of glucocorticoid receptor (GR) signaling, personality dimensions and recent stressful life events. Methods. Seventy participants -35 diagnosed with major depression and 35 healthy controls, were enrolled in the study. Morning plasma cortisol levels were determined by chemiluminescent immunometric assays. Molecular parameters (total nuclear and cytoplasmatic GR, nuclear GR phosphorylated at serine 211 (pGR-211) and at serine 226 (pGR-226) and cytoplasmic FKBP51) were analysed from peripheral blood lymphocytes by Western blot. NA, personality dimensions and stressful life events were assessed by self-report instruments. Results. GR signalling parameters had direct independent effect on measures of NA, with pGR-226 levels showing the strongest correlation, followed by FKBP51 and pGR-211 levels. Neuroticism and extraversion also demonstrated strong independent effect on NA, while recent stressful events did not predict NA directly, but demonstrated a significant effect on personality dimensions. Cortisol, total nuclear GR and total cytoplasmatic GR levels were excluded from the model due to non-significant correlations with NA. Conclusions. Negative affectivity is a transdiagnostic factor in vulnerability to affective disorders and possible therapeutic target. Molecular signature of negative affectivity should incorporate GR phosphorylation with other known biological underpinnings.
T2  - World Journal of Biological Psychiatry
T1  - The role of glucocorticoid receptor phosphorylation in the model of negative affective states
VL  - 16
IS  - 5
SP  - 301
EP  - 311
DO  - 10.3109/15622975.2014.1000375
ER  - 

@article{
author = "Jovičić, Milica and Marić, Nađa P. and Soldatovic, Ivan and Lukić, Iva and Andrić, Sanja and Mihaljević, Marina and Pavlović, Zorana and Mitić, Miloš and Adžić, Miroslav",
year = "2015",
abstract = "Objectives. To develop a structural equation model of negative affectivity (NA) that involves interaction of glucocorticoid receptor (GR) signaling, personality dimensions and recent stressful life events. Methods. Seventy participants -35 diagnosed with major depression and 35 healthy controls, were enrolled in the study. Morning plasma cortisol levels were determined by chemiluminescent immunometric assays. Molecular parameters (total nuclear and cytoplasmatic GR, nuclear GR phosphorylated at serine 211 (pGR-211) and at serine 226 (pGR-226) and cytoplasmic FKBP51) were analysed from peripheral blood lymphocytes by Western blot. NA, personality dimensions and stressful life events were assessed by self-report instruments. Results. GR signalling parameters had direct independent effect on measures of NA, with pGR-226 levels showing the strongest correlation, followed by FKBP51 and pGR-211 levels. Neuroticism and extraversion also demonstrated strong independent effect on NA, while recent stressful events did not predict NA directly, but demonstrated a significant effect on personality dimensions. Cortisol, total nuclear GR and total cytoplasmatic GR levels were excluded from the model due to non-significant correlations with NA. Conclusions. Negative affectivity is a transdiagnostic factor in vulnerability to affective disorders and possible therapeutic target. Molecular signature of negative affectivity should incorporate GR phosphorylation with other known biological underpinnings.",
journal = "World Journal of Biological Psychiatry",
title = "The role of glucocorticoid receptor phosphorylation in the model of negative affective states",
volume = "16",
number = "5",
pages = "301-311",
doi = "10.3109/15622975.2014.1000375"
}

Jovičić, M., Marić, N. P., Soldatovic, I., Lukić, I., Andrić, S., Mihaljević, M., Pavlović, Z., Mitić, M.,& Adžić, M.. (2015). The role of glucocorticoid receptor phosphorylation in the model of negative affective states. in World Journal of Biological Psychiatry, 16(5), 301-311.
https://doi.org/10.3109/15622975.2014.1000375

Jovičić M, Marić NP, Soldatovic I, Lukić I, Andrić S, Mihaljević M, Pavlović Z, Mitić M, Adžić M. The role of glucocorticoid receptor phosphorylation in the model of negative affective states. in World Journal of Biological Psychiatry. 2015;16(5):301-311.
doi:10.3109/15622975.2014.1000375 .

Jovičić, Milica, Marić, Nađa P., Soldatovic, Ivan, Lukić, Iva, Andrić, Sanja, Mihaljević, Marina, Pavlović, Zorana, Mitić, Miloš, Adžić, Miroslav, "The role of glucocorticoid receptor phosphorylation in the model of negative affective states" in World Journal of Biological Psychiatry, 16, no. 5 (2015):301-311,
https://doi.org/10.3109/15622975.2014.1000375 . .

TY  - JOUR
AU  - Lukić, Iva
AU  - Mitić, Miloš
AU  - Đorđević, Jelena D.
AU  - Tatalović, Nikola R.
AU  - Božović, Natalija
AU  - Soldatovic, Ivan
AU  - Mihaljević, Marina
AU  - Pavlović, Zorana
AU  - Radojčić, Marija
AU  - Marić, Nađa P.
AU  - Adžić, Miroslav
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/148
AB  - Background: Oxidative stress is reliably observed in major depressive disorder (MDD). However, molecular data on the principal cellular redox-sensitive transcriptional factors and the levels of their downstream-regulated antioxidant enzymes in MDD are scarce. Methods: In the peripheral blood mononuclear cells (PBMC) of subjects with a current episode of MDD (n = 30) and healthy controls (n = 35), we investigated alterations in the levels of redox-sensing nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein, its inhibitor Keap1, and nuclear factor-kappa B (NF-kappa B), along with their cognate downstream effectors, the antioxidant enzymes (AOEs): manganese and copper zinc superoxide dismutase (MnSOD and CuZnSOD, respectively), catalase (CAT), glutathione peroxidase (GPx) and glutathione reductase (GLR). Results: MDD subjects exhibited higher levels of Nrf2 and its regulator Keap1, as well as NF-kappa B in the cytoplasm of PBMC compared to controls. This state was further reflected by increased levels of MnSOD, CuZnSOD and CAT proteins and by the lack of correlation between MnSOD and CAT, which could indicate impaired oxidative detoxification capacity in MDD patients. Moreover, increased levels of MnSOD, CuZnSOD and CAT in MDD patients positively correlated with levels of Nrf2, while increased levels of SODs were also positively related to NF-kappa B. There were no differences regarding the levels of GPx and GLR proteins, but the ratio of GLR/GPx was reduced, suggesting diminished capacity of GPx in antioxidative defence in PBMC of MDD subjects. Conclusion: These data provide evidence that MDD is characterized by up-regulation of redox-sensitive transcriptional factors (Nrf2 and NF-kappa B) and AOEs (MnSOD, CuZnSOD and CAT), indicating pro-oxidative state in the PBMC of MDD patients. (C) 2014 S. Karger AG, Basel
T2  - Neuropsychobiology
T1  - Lymphocyte Levels of Redox-Sensitive Transcription Factors and Antioxidative Enzymes as Indicators of Pro-Oxidative State in Depressive Patients
VL  - 70
IS  - 1
SP  - 1
EP  - 9
DO  - 10.1159/000362841
ER  - 

@article{
author = "Lukić, Iva and Mitić, Miloš and Đorđević, Jelena D. and Tatalović, Nikola R. and Božović, Natalija and Soldatovic, Ivan and Mihaljević, Marina and Pavlović, Zorana and Radojčić, Marija and Marić, Nađa P. and Adžić, Miroslav",
year = "2014",
abstract = "Background: Oxidative stress is reliably observed in major depressive disorder (MDD). However, molecular data on the principal cellular redox-sensitive transcriptional factors and the levels of their downstream-regulated antioxidant enzymes in MDD are scarce. Methods: In the peripheral blood mononuclear cells (PBMC) of subjects with a current episode of MDD (n = 30) and healthy controls (n = 35), we investigated alterations in the levels of redox-sensing nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein, its inhibitor Keap1, and nuclear factor-kappa B (NF-kappa B), along with their cognate downstream effectors, the antioxidant enzymes (AOEs): manganese and copper zinc superoxide dismutase (MnSOD and CuZnSOD, respectively), catalase (CAT), glutathione peroxidase (GPx) and glutathione reductase (GLR). Results: MDD subjects exhibited higher levels of Nrf2 and its regulator Keap1, as well as NF-kappa B in the cytoplasm of PBMC compared to controls. This state was further reflected by increased levels of MnSOD, CuZnSOD and CAT proteins and by the lack of correlation between MnSOD and CAT, which could indicate impaired oxidative detoxification capacity in MDD patients. Moreover, increased levels of MnSOD, CuZnSOD and CAT in MDD patients positively correlated with levels of Nrf2, while increased levels of SODs were also positively related to NF-kappa B. There were no differences regarding the levels of GPx and GLR proteins, but the ratio of GLR/GPx was reduced, suggesting diminished capacity of GPx in antioxidative defence in PBMC of MDD subjects. Conclusion: These data provide evidence that MDD is characterized by up-regulation of redox-sensitive transcriptional factors (Nrf2 and NF-kappa B) and AOEs (MnSOD, CuZnSOD and CAT), indicating pro-oxidative state in the PBMC of MDD patients. (C) 2014 S. Karger AG, Basel",
journal = "Neuropsychobiology",
title = "Lymphocyte Levels of Redox-Sensitive Transcription Factors and Antioxidative Enzymes as Indicators of Pro-Oxidative State in Depressive Patients",
volume = "70",
number = "1",
pages = "1-9",
doi = "10.1159/000362841"
}

Lukić, I., Mitić, M., Đorđević, J. D., Tatalović, N. R., Božović, N., Soldatovic, I., Mihaljević, M., Pavlović, Z., Radojčić, M., Marić, N. P.,& Adžić, M.. (2014). Lymphocyte Levels of Redox-Sensitive Transcription Factors and Antioxidative Enzymes as Indicators of Pro-Oxidative State in Depressive Patients. in Neuropsychobiology, 70(1), 1-9.
https://doi.org/10.1159/000362841

Lukić I, Mitić M, Đorđević JD, Tatalović NR, Božović N, Soldatovic I, Mihaljević M, Pavlović Z, Radojčić M, Marić NP, Adžić M. Lymphocyte Levels of Redox-Sensitive Transcription Factors and Antioxidative Enzymes as Indicators of Pro-Oxidative State in Depressive Patients. in Neuropsychobiology. 2014;70(1):1-9.
doi:10.1159/000362841 .

Lukić, Iva, Mitić, Miloš, Đorđević, Jelena D., Tatalović, Nikola R., Božović, Natalija, Soldatovic, Ivan, Mihaljević, Marina, Pavlović, Zorana, Radojčić, Marija, Marić, Nađa P., Adžić, Miroslav, "Lymphocyte Levels of Redox-Sensitive Transcription Factors and Antioxidative Enzymes as Indicators of Pro-Oxidative State in Depressive Patients" in Neuropsychobiology, 70, no. 1 (2014):1-9,
https://doi.org/10.1159/000362841 . .

TY  - JOUR
AU  - Simić, Iva
AU  - Marić, Nađa P.
AU  - Mitić, Miloš
AU  - Soldatovic, Ivan
AU  - Pavlović, Zorana
AU  - Mihaljević, Marina
AU  - Andrić, Sanja
AU  - Radoičić, Marija B.
AU  - Adžić, Miroslav
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5340
AB  - The impaired glucocorticoid receptor (GR) signaling has long been considered one of the cornerstones in understanding the pathophysiology of depression. Since the phosphorylation of GR is very important for GR function, in this study we investigated whether GR phosphorylation at serine 211 (pGR-S211) and serine 226 (pGR-S226) is altered in patients with current episode of major depressive disorder (MDD). Particularly, in 30 MDD patients and 35 controls we assessed the levels of nuclear total GR (tGR), pGR-S211 and pGR-S226 in peripheral blood mononuclear cells (PBMC) using Western blot technique, along with plasma cortisol concentrations from the same blood samples. Our results demonstrated increased phosphorylation of GR at S226 (p LT 0.001) and, to a less extent, at S211 (p LT 0.05) in MDD patients compared to controls. Consequently, the pGR-S211/pGR-S226 ratio was decreased (p LT 0.05) implying reduced transcriptional activity of GR in MDD patients. MDD subjects had higher cortisol levels than controls and cortisol concentrations were positively correlated with PBMC pGR-S226 levels from the same blood samples. There was no difference in the levels of tGR between MDD and control subjects. The study showed that altered phosphorylation of GR could contribute to impaired GR function related to the pathophysiology of depression. (c) 2012 Elsevier Inc. All rights reserved.
T2  - Progress in Neuro-psychopharmacology and Biological Psychiatry
T1  - Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder
VL  - 40
SP  - 281
EP  - 285
DO  - 10.1016/j.pnpbp.2012.10.021
ER  - 

@article{
author = "Simić, Iva and Marić, Nađa P. and Mitić, Miloš and Soldatovic, Ivan and Pavlović, Zorana and Mihaljević, Marina and Andrić, Sanja and Radoičić, Marija B. and Adžić, Miroslav",
year = "2013",
abstract = "The impaired glucocorticoid receptor (GR) signaling has long been considered one of the cornerstones in understanding the pathophysiology of depression. Since the phosphorylation of GR is very important for GR function, in this study we investigated whether GR phosphorylation at serine 211 (pGR-S211) and serine 226 (pGR-S226) is altered in patients with current episode of major depressive disorder (MDD). Particularly, in 30 MDD patients and 35 controls we assessed the levels of nuclear total GR (tGR), pGR-S211 and pGR-S226 in peripheral blood mononuclear cells (PBMC) using Western blot technique, along with plasma cortisol concentrations from the same blood samples. Our results demonstrated increased phosphorylation of GR at S226 (p LT 0.001) and, to a less extent, at S211 (p LT 0.05) in MDD patients compared to controls. Consequently, the pGR-S211/pGR-S226 ratio was decreased (p LT 0.05) implying reduced transcriptional activity of GR in MDD patients. MDD subjects had higher cortisol levels than controls and cortisol concentrations were positively correlated with PBMC pGR-S226 levels from the same blood samples. There was no difference in the levels of tGR between MDD and control subjects. The study showed that altered phosphorylation of GR could contribute to impaired GR function related to the pathophysiology of depression. (c) 2012 Elsevier Inc. All rights reserved.",
journal = "Progress in Neuro-psychopharmacology and Biological Psychiatry",
title = "Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder",
volume = "40",
pages = "281-285",
doi = "10.1016/j.pnpbp.2012.10.021"
}

Simić, I., Marić, N. P., Mitić, M., Soldatovic, I., Pavlović, Z., Mihaljević, M., Andrić, S., Radoičić, M. B.,& Adžić, M.. (2013). Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder. in Progress in Neuro-psychopharmacology and Biological Psychiatry, 40, 281-285.
https://doi.org/10.1016/j.pnpbp.2012.10.021

Simić I, Marić NP, Mitić M, Soldatovic I, Pavlović Z, Mihaljević M, Andrić S, Radoičić MB, Adžić M. Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder. in Progress in Neuro-psychopharmacology and Biological Psychiatry. 2013;40:281-285.
doi:10.1016/j.pnpbp.2012.10.021 .

Simić, Iva, Marić, Nađa P., Mitić, Miloš, Soldatovic, Ivan, Pavlović, Zorana, Mihaljević, Marina, Andrić, Sanja, Radoičić, Marija B., Adžić, Miroslav, "Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder" in Progress in Neuro-psychopharmacology and Biological Psychiatry, 40 (2013):281-285,
https://doi.org/10.1016/j.pnpbp.2012.10.021 . .

TY  - JOUR
AU  - Marić, Nađa P.
AU  - Adžić, Miroslav
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/6063
AB  - One of the most consistent biological findings in major depression (MDD) is the altered activity of the hypothalamic-pituitary-adrenal (HPA) axis. It is not surprising that glucocorticoid receptor (GR), the common mechanism for stress-related changes in brain function, is a potential target of antidepressant drugs and therapies. All effective antidepressant treatments should trigger and maintain GR-related cellular processes necessary for recovery from MDD. Classic antidepressants act indirectly, by affecting the dynamic interplay between serotonin neurotransmission and HPA. On the other hand, certain compounds acting at supra-hypothalamic, HPA axis, glucocorticoid receptors, and post-receptor levels are being considered as new therapeutic options with the potential to modulate the aforementioned system in affective disorders directly. Different classes of drugs pharmacologically modify the HPA axis. This article summarizes the efficacy of classic antidepressants, as well as drugs classified as antiglucocorticoids (GR agonists, GR antagonists, dehydroepiandrosterone-DHEA, steroid synthesis inhibitors drugs, etc) in their capacity to heal glucocorticoid-mediated damage in depression. New avenues investigating the potential therapeutic benefits of antiglucocorticoids in affective disorders are at the proof-of-concept stage and future developments in this area deserve the full attention of psychiatrists and neuroscientists, as the current pharmacological treatment of MDD is far from perfect.
T2  - Psychiatria Danubina
T1  - Pharmacological Modulation of HPA Axis in Depression - New Avenues for Potential Therapeutic Benefits
VL  - 25
IS  - 3
SP  - 299
EP  - 305
UR  - https://hdl.handle.net/21.15107/rcub_vinar_6063
ER  - 

@article{
author = "Marić, Nađa P. and Adžić, Miroslav",
year = "2013",
abstract = "One of the most consistent biological findings in major depression (MDD) is the altered activity of the hypothalamic-pituitary-adrenal (HPA) axis. It is not surprising that glucocorticoid receptor (GR), the common mechanism for stress-related changes in brain function, is a potential target of antidepressant drugs and therapies. All effective antidepressant treatments should trigger and maintain GR-related cellular processes necessary for recovery from MDD. Classic antidepressants act indirectly, by affecting the dynamic interplay between serotonin neurotransmission and HPA. On the other hand, certain compounds acting at supra-hypothalamic, HPA axis, glucocorticoid receptors, and post-receptor levels are being considered as new therapeutic options with the potential to modulate the aforementioned system in affective disorders directly. Different classes of drugs pharmacologically modify the HPA axis. This article summarizes the efficacy of classic antidepressants, as well as drugs classified as antiglucocorticoids (GR agonists, GR antagonists, dehydroepiandrosterone-DHEA, steroid synthesis inhibitors drugs, etc) in their capacity to heal glucocorticoid-mediated damage in depression. New avenues investigating the potential therapeutic benefits of antiglucocorticoids in affective disorders are at the proof-of-concept stage and future developments in this area deserve the full attention of psychiatrists and neuroscientists, as the current pharmacological treatment of MDD is far from perfect.",
journal = "Psychiatria Danubina",
title = "Pharmacological Modulation of HPA Axis in Depression - New Avenues for Potential Therapeutic Benefits",
volume = "25",
number = "3",
pages = "299-305",
url = "https://hdl.handle.net/21.15107/rcub_vinar_6063"
}

Marić, N. P.,& Adžić, M.. (2013). Pharmacological Modulation of HPA Axis in Depression - New Avenues for Potential Therapeutic Benefits. in Psychiatria Danubina, 25(3), 299-305.
https://hdl.handle.net/21.15107/rcub_vinar_6063

Marić NP, Adžić M. Pharmacological Modulation of HPA Axis in Depression - New Avenues for Potential Therapeutic Benefits. in Psychiatria Danubina. 2013;25(3):299-305.
https://hdl.handle.net/21.15107/rcub_vinar_6063 .

Marić, Nađa P., Adžić, Miroslav, "Pharmacological Modulation of HPA Axis in Depression - New Avenues for Potential Therapeutic Benefits" in Psychiatria Danubina, 25, no. 3 (2013):299-305,
https://hdl.handle.net/21.15107/rcub_vinar_6063 .